Literature DB >> 16195861

[Significance of the PSA-concentration for the detection of prostate cancer].

A Stachon1.   

Abstract

Prostate cancer among adult males is the most common neoplasm in western countries. Prostate specific antigen (PSA) is now a well established tumor marker that aids in the early detection of localized prostate cancer. Increased PSA concentrations are found in the serum of patients with benign prostatic hyperplasia or patients with prostate cancer, respectively. Therefore, in general the specificity of this test is low. The diagnostic value of PSA can be improved in consideration of clinical data, patients age, the measurement of free or complexed PSA, and the measurement of PSA velocity, respectively. Furthermore, there is a high variability between commercial PSA assays. Finally, the pre-analytical laboratory procedures have a high impact on the PSA measurement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195861     DOI: 10.1007/s00292-005-0788-8

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  15 in total

1.  Low levels of PSA predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging.

Authors:  F H Schröder; M F Wildhagen
Journal:  Urology       Date:  2002-03       Impact factor: 2.649

2.  The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen.

Authors:  F Oberpenning; H-P Schmid; W Fuchs-Surdel; L Hertle; A Semjonow
Journal:  Int J Biol Markers       Date:  2002 Jul-Sep       Impact factor: 2.659

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared.

Authors:  K Jung; C Stephan; M Lein; W Henke; D Schnorr; B Brux; P Schürenkämper; S A Loening
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

5.  Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.

Authors:  Koji Okihara; Carol D Cheli; Alan W Partin; Herbert A Fritche; Daniel W Chan; Lori J Sokoll; Michael K Brawer; Morton K Schwartz; Robert L Vessella; Kevin R Loughlin; Dennis A Johnston; R Joseph Babaian
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

6.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.

Authors:  A Christensson; C B Laurell; H Lilja
Journal:  Eur J Biochem       Date:  1990-12-27

7.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

Review 8.  Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

Authors:  S Jain; A G Bhojwani; J K Mellon
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

Review 9.  The complex genetic epidemiology of prostate cancer.

Authors:  Daniel J Schaid
Journal:  Hum Mol Genet       Date:  2004-01-28       Impact factor: 6.150

10.  [Effect of the natural history on management of adenocarcinoma of the prostate].

Authors:  H P Schmid; T A Stamey; J E McNeal; F S Freiha; E A Redwine; A S Whittemore
Journal:  Urologe A       Date:  1994-03       Impact factor: 0.639

View more
  1 in total

1.  Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.

Authors:  Shu-Yu Tai; Shu-Pin Huang; Bo-Ying Bao; Ming-Tsang Wu
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.